Drugs / rBCG-N-hRSV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03213405 | Jun 2017 → Jun 2018 | respiratory syncytial virus infectious disease | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rBCG-N-hRSV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03213405 ↗ |
| Modality | Vaccine | “a recombinant Mycobacterium bovis BCG vaccine that expresses the human Respiratory Syncytial Virus Nucleoprotein (N)” NCT03213405 ↗ |
| Route | Other | “5x10\^3 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.” NCT03213405 ↗ |